Almost every dosing or administration figure attached to IGF-1 LR3 comes from the bench or the animal facility, not from human medicine, and that single fact reframes the entire question. The published record treats the peptide as a laboratory reagent: cell-culture concentrations in nanograms per milliliter, animal doses scaled to body weight, and a research-use-only label that keeps all of it outside approved clinical use. No approved indication and no defining human trial program exists to set a therapeutic window, so the literature offers no human recipe to read off.
IGF-1 LR3 appears throughout the research literature as a laboratory reagent with no approved human indication and no established dosing protocol, so every concentration and body-weight figure it carries is a bench or animal parameter rather than a human dose.
In cell-culture work the reported concentrations sit in the nanograms-per-milliliter range or the low nanomolar band, set to drive a measurable receptor signal in a small, static volume of media. Researchers arrive at that value experimentally rather than by convention, and a common role for the peptide is standing in for serum in defined media. The number describes the local environment around cells in a dish, not a quantity delivered to a whole organism.
In vitro protocols report IGF-1 LR3 in nanograms per milliliter or the low nanomolar range, a description of the media surrounding cultured cells that cannot be read as, or converted into, a human dose.
Preclinical designs deliver IGF-1 LR3 parenterally, most often by subcutaneous or intraperitoneal injection in rodents, and some hold a steady exposure with an implanted osmotic pump rather than a single bolus. Amounts are expressed against the animal's body weight and tuned to the endpoint under study. The species and the route are chosen for the experiment, which is exactly why the schedule does not transfer to a person: metabolism, clearance, and receptor distribution differ across species, and allometric scaling is not a simple multiplier.
Preclinical studies administer IGF-1 LR3 by subcutaneous injection, intraperitoneal injection, or implanted osmotic pump at body-weight-scaled amounts in micrograms or milligrams per kilogram, none of which translate linearly to human physiology.
A dish concentration and a human dose are not two points on one scale, so no conversion between them holds. The plate has a fixed volume, no bloodstream, no organs, and no clearance; a living body adds absorption, distribution, metabolism, excretion, and a system of binding proteins and feedback loops that continually reshape how much active peptide reaches a target. Reading a per-milliliter figure as though it implies a milligram amount for a person is a category error, not a calculation.
| Factor | Cell-culture dish | Human dose |
|---|---|---|
| Volume | Fixed, static media | Distributed through blood and tissue |
| Clearance | None | Metabolism and excretion continually remove it |
| Binding proteins | Largely absent | IGFBPs and feedback loops reshape free peptide |
| Endpoint | Receptor saturation in a well | Systemic safety and exposure across organs |
Bridging an in vitro concentration to a defensible human dose requires the full arc of pharmacokinetic, toxicology, and controlled clinical testing that a research reagent has never undergone, which is why no valid conversion between the two exists.
The LR3 name records two engineered changes to native IGF-1, and together they are what make the molecule useful at the bench and hazardous to extrapolate from. Both changes reduce capture by the IGF binding proteins that would normally sequester circulating IGF-1, leaving more of it free to engage the IGF-1 receptor. In research models that reads as greater apparent potency and a longer duration of action than native IGF-1 at a matched concentration.
The LR3 modification's reduced IGF-binding-protein affinity produces greater apparent potency and a longer duration of action in research models, and that same engineered persistence would be harder to buffer or reverse in a living system.
Laboratory protocols describe IGF-1 LR3 as a lyophilized powder reconstituted before use and then diluted into a buffer or media suited to the experiment. The handling notes are quality-control steps meant to preserve a reagent's integrity for bench work, and they sit under a research-use-only label that explicitly excludes human or clinical use. Detailed storage instructions describe how to keep a peptide stable in a vial; they say nothing about whether, how, or how much of it could ever be appropriate for a person.
The handling, reconstitution, and storage steps in laboratory protocols are reagent quality-control instructions under a research-use-only label, not a dosing protocol and not permission to administer the material.
IGF-1 LR3 is sold under a research-use-only designation, which means it is intended for laboratory investigation and is not authorized, labeled, or quality-assured for administration to people. It has never completed the clinical-trial program that produces an approved medicine with an official dose and prescribing information, and anti-doping bodies list IGF-1 and its analogs as prohibited substances. That regulatory status is the direct reason no sanctioned dose exists.
IGF-1 LR3 carries a research-use-only designation and no regulatory approval because it has never completed the clinical trials that define an official dose, so any administration to a person falls entirely outside the approved system.
Self-administration strips away every safeguard a clinical setting provides while stacking several distinct hazards on top of one another. The product itself carries no assurance of identity, purity, or sterility, and the biology underneath it is potent: IGF-1 signaling influences glucose metabolism and is linked to serious hypoglycemia, and as a growth factor it raises a well-founded theoretical concern about promoting abnormal or existing tissue growth. Without a clinician there is no baseline assessment, no monitoring, and no one positioned to catch an adverse reaction.
The combination of an uncharacterized injectable product, a potent metabolically active growth factor linked to serious hypoglycemia, and the total absence of monitoring is why administration outside a licensed clinician's care is the central risk this literature raises.
An established dosing protocol is the output of a deliberate scientific process that IGF-1 LR3 has never been carried through for human use. Without dose-finding studies, pharmacokinetic and toxicology work, and controlled clinical trials, its therapeutic window in people, the gap between a useful amount and a harmful one, is simply undefined. Amounts circulated anecdotally or within user communities are not derived from controlled evidence and do not convert into a validated standard through repetition.
Because IGF-1 LR3 has never completed the dose-finding, pharmacokinetic, toxicology, and controlled clinical trials that define an official dose, its human therapeutic window is undefined and any administration decision rests solely with a licensed clinician for a specific patient.
Educational use only. This article describes what the published scientific and clinical literature reports about IGF-1 LR3. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
